Tech Company Financing Transactions

Broken String Biosciences Funding Round

Broken String Biosciences, based in Cambridge, England, raised $15 million in investment from Illumina Ventures, Dieter von Holtzbrinck Ventures and Heran Partners.

Transaction Overview

Company Name
Broken String Biosciences
Announced On
9/18/2023
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Investors

Illumina Ventures (Lead Investor)

Dieter von Holtzbrinck Ventures

Heran Partners

private investors (Arnaud Autret)

private investors (Yoann Bonnamour)

Mérieux Equity Partners

Tencent

Proceeds Purpose
The company intends to use the funds to develop its Next Generation Sequencing (NGS)-based DNA break mapping platform, INDUCE-seq�, into a scalable 'Platform as a Service' (PaaS) offering, and to expand its capabilities beyond gene editing, broadening its go-to-market strategy and driving commercial traction. The investment also supports its ongoing growth, including recruitment for its UK team based at the Wellcome Genome Campus, Cambridge, and the establishment of a US office.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Unit AB3-04, Level 3 BioData Innovation Centre Wellcome Geno
Cambridge, England, CB10 1DR
UK
Phone
+44(0)1223 786 071
Website
www.brokenstringbio.com
Email Address
[email protected]
Overview
Broken String Biosciences is building a technology platform that accelerates the characterisation of novel genome editing technologies. This will unlock the next wave of cell & gene therapies. Our vision is a future where cell & gene therapies are safer, more efficient, and affordable for patients. Starting with our DNA break mapping technology INDUCE-seq�, our data-driven platform reveals precisely how genome editors interact with and alter our genomes. This information is essential for the efficient development of novel genome editing systems and will unlock many new targets within the genome for therapeutic development.
Profile
Broken String Biosciences LinkedIn Company Profile
Social Media
Broken String Biosciences Company Twitter Account
Company News
Broken String Biosciences News
Facebook
Broken String Biosciences on Facebook
YouTube
Broken String Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Felix Dobbs
  Felix Dobbs LinkedIn Profile  Felix Dobbs Twitter Account  Felix Dobbs News  Felix Dobbs on Facebook
Chief Scientific Officer
Simon Reed
  Simon Reed LinkedIn Profile  Simon Reed Twitter Account  Simon Reed News  Simon Reed on Facebook
Co-Founder
Patrick Eijk
  Patrick Eijk LinkedIn Profile  Patrick Eijk Twitter Account  Patrick Eijk News  Patrick Eijk on Facebook
Co-Founder
Simon Kerr
  Simon Kerr LinkedIn Profile  Simon Kerr Twitter Account  Simon Kerr News  Simon Kerr on Facebook

 

 

Browse more venture capital transactions:

Prev: 9/18/2023: Boxbot venture capital transaction
Next: 9/18/2023: Dragos venture capital transaction

 

Share this article

 

About Database of VC Transactions

We report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.